Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra
NEWS 16 MAR 31 CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:33:08 ON 17 MAY 2008

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 11:33:26 ON 17 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 May 2008 VOL 148 ISS 21
FILE LAST UPDATED: 16 May 2008 (20080516/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s (cell-penetrating peptid?)
      2393962 CELL
      2066630 CELLS
      3133503 CELL
              (CELL OR CELLS)
        26237 PENETRATING
       530263 PEPTID?
L1        618 (CELL-PENETRATING PEPTID?)
              (CELL(W)PENETRATING(W)PEPTID?)

=> s (sc-fv or scfv or (single chain fv))
        50582 SC
         3177 SCS
        53354 SC
              (SC OR SCS)
         7672 FV
          221 FVS
         7765 FV
              (FV OR FVS)
            8 SC-FV
              (SC(W)FV)
         4182 SCFV
          575 SCFVS
         4245 SCFV
              (SCFV OR SCFVS)
      1418057 SINGLE
         3401 SINGLES
      1420946 SINGLE
              (SINGLE OR SINGLES)
       765096 CHAIN
       332456 CHAINS
       960894 CHAIN
              (CHAIN OR CHAINS)
         7672 FV
          221 FVS
         7765 FV
              (FV OR FVS)
         1711 SINGLE CHAIN FV
              (SINGLE(W)CHAIN(W)FV)
L2       4764 (SC-FV OR SCFV OR (SINGLE CHAIN FV))

=> s L1 and l2
L3          2 L1 AND L2
```

=> d l3 bib abs 1-2

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:972196 CAPLUS
DN 143:244215
TI Penetratin Improves Tumor Retention of Single-Chain Antibodies: A Novel Step toward Optimization of Radioimmunotherapy of Solid Tumors
AU Jain, Maneesh; Chauhan, Subhash C.; Singh, Ajay P.; Venkatraman, Ganesh; Colcher, David; Batra, Surinder K.
CS Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA
SO Cancer Research (2005), 65(17), 7840-7846
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB Single-chain Fv (scFv) antibody fragments exhibit improved pharmacokinetics and biodistribution compared with intact IgG. The tumor uptake of scFvs is rapid, and the serum half-life is shorter than IgG. However, scFvs exhibit lower net dose deposition in the tumor due to a shorter residence time that limits their use in radioimmunotherapy. To improve the tumor uptake and retention of scFvs, we investigated the utility of cell-penetrating peptides, penetratin and transactivator of transcription (TAT). Biodistribution studies were done in LS174T tumor-bearing mice with divalent scFv derived from anti-tumor-assocd. glycoprotein 72 monoclonal antibody (mAb) CC49. Penetratin increased the tumor retention of scFvs without affecting the peak dose accumulation. The percentage of doses retained in tumors at 24 h postadministration with a control (no peptide), penetratin, and TAT were 27.25%, 79.84%, and 48.55%, resp., of that accumulated at 8 h postinjection. The tumor-to-blood ratios at 24 h postadministration were 7.14, 19.53, and 16.48 with control, penetratin, and TAT treatment, resp., whereas the pharmacokinetics were unaltered. Coinjection with TAT, however, resulted in increased uptake of the radioconjugate by the lungs. Autoradiog. of the excised tumors indicated a more homogenous distribution of the radiolabeled scFv with both penetratin and TAT in comparison with the control treatment. Real-time whole-body imaging of the live animals confirmed improved tumor localization with penetratin without any increase in the uptake by normal tissues. In conclusion, a significant improvement in the tumor retention of s.c.(Fv)2 was achieved by administration of penetratin. Therefore, the combination of penetratin and scFvs has the potential of improving the utility of mAb-based radiopharmaceuticals.

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:267364 CAPLUS
DN 140:302337
TI Preparation and use of therapeutic antibodies entering into the cell
IN Valkna, Andres; Kogerman, Priit
PA Inbio Oue, Estonia
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004026911	A1	20040401	WO 2003-EE5	20030916
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EE 200200531	A	20040415	EE 2002-531	20020917
CA 2499321	A1	20040401	CA 2003-2499321	20030916
AU 2003266225	A1	20040408	AU 2003-266225	20030916
EP 1539823	A1	20050615	EP 2003-797197	20030916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20080063633	A1	20080313	US 2005-528073	20050317
PRAI EE 2002-531	A	20020917		
WO 2003-EE5	W	20030916		

AB The disclosed invention relates to the development of a novel technol. of (cancer-)specific antibodies entering into the cell and their use for treatment of human diseases (primarily cancer). Such antibody (drug) would act by directly modulating the cancer-generating signals. The expected effects and principles of action of such antibodies are inactivation of intracellular proteins and thus they could be used for the treatment of diseases, where the activity of intracellular proteins must be modulated for effective treatment (primarily malignant tumors, but also many other diseases, which can be treated by inactivation of intracellular

proteins). The invention relates to the use of peptide vector mols. (cell-penetrating peptides, CPPs), preferably peptide transportan (or its shorter analog transportan TP10), a combination of neuropeptide galanin and wasp venom peptide mastoparan fragments. In examples presented here, these CPPs are conjugated to monoclonal (or polyclonal) antibodies to GLI proteins, assocd. with signaling in basal cell carcinoma pathogenesis. These recombinant antibodies were shown to enter the cultured cells. The same results were obtained when the single-chain (scFv) antibody fragments were used in the recombinant protein.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (single chain antibody?)

1418057 SINGLE

3401 SINGLES

1420946 SINGLE

(SINGLE OR SINGLES)

765096 CHAIN

332456 CHAINS

960894 CHAIN

(CHAIN OR CHAINS)

329386 ANTIBODY?

L4 2130 (SINGLE CHAIN ANTIBODY?)

(SINGLE(W)CHAIN(W)ANTIBODY?)

=> s L1 and L4

L5 0 L1 AND L4

=> s (single chain antibod?)

1418057 SINGLE

3401 SINGLES

1420946 SINGLE

(SINGLE OR SINGLES)

765096 CHAIN

332456 CHAINS

960894 CHAIN

(CHAIN OR CHAINS)

522810 ANTIBOD?

L6 2550 (SINGLE CHAIN ANTIBOD?)

(SINGLE(W)CHAIN(W)ANTIBOD?)

=> s L1 and L6

L7 1 L1 AND L6

=> d l7 bib abs 1

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:972196 CAPLUS
DN 143:244215
TI Penetratin Improves Tumor Retention of Single-Chain Antibodies: A Novel Step toward Optimization of Radioimmunotherapy of Solid Tumors
AU Jain, Maneesh; Chauhan, Subhash C.; Singh, Ajay P.; Venkatraman, Ganesh; Colcher, David; Batra, Surinder K.
CS Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA
SO Cancer Research (2005), 65(17), 7840-7846
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB Single-chain Fv (scFv) antibody fragments exhibit improved pharmacokinetics and biodistribution compared with intact IgG. The tumor uptake of scFvs is rapid, and the serum half-life is shorter than IgG. However, scFvs exhibit lower net dose deposition in the tumor due to a shorter residence time that limits their use in radioimmunotherapy. To improve the tumor uptake and retention of scFvs, we investigated the utility of cell-penetrating peptides, penetratin and transactivator of transcription (TAT). Biodistribution studies were done in LS174T tumor-bearing mice with divalent scFv derived from anti-tumor-assocd. glycoprotein 72 monoclonal antibody (mAb) CC49. Penetratin increased the tumor retention of scFvs without affecting the peak dose accumulation. The percentage of doses retained in tumors at 24 h postadministration with a control (no peptide), penetratin, and TAT were 27.25%, 79.84%, and 48.55%, resp., of that accumulated at 8 h postinjection. The tumor-to-blood ratios at 24 h postadministration were 7.14, 19.53, and 16.48 with control, penetratin, and TAT treatment, resp., whereas the pharmacokinetics were unaltered. Coinjection with TAT, however, resulted in increased uptake of the radioconjugate by the lungs. Autoradiog. of the excised tumors indicated a more homogenous distribution of the radiolabeled scFv with both penetratin and TAT in comparison with the control treatment. Real-time whole-body imaging of the live animals confirmed improved tumor localization with penetratin without any increase in the uptake by normal tissues. In conclusion, a significant improvement in the tumor retention of s.c.(Fv)2 was achieved by administration of penetratin. Therefore, the combination of penetratin and scFvs has the potential of improving the utility of mAb-based radiopharmaceuticals.
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s (transport peptide)
       784339 TRANSPORT
         6737 TRANSPORTS
       787076 TRANSPORT
              (TRANSPORT OR TRANSPORTS)
       394289 PEPTIDE
       287255 PEPTIDES
       503184 PEPTIDE
              (PEPTIDE OR PEPTIDES)
L8        331 (TRANSPORT PEPTIDE)
              (TRANSPORT(W)PEPTIDE)

=> display history
ENTER (BRIEF), FULL, OR NOFILE:brief
ENTER (L1-), L#, OR ?:L1

    (FILE 'HOME' ENTERED AT 11:33:08 ON 17 MAY 2008)

    FILE 'CAPLUS' ENTERED AT 11:33:26 ON 17 MAY 2008
L1        618 S (CELL-PENETRATING PEPTID?)

=> se L8 and (sc-fv or scfv or (single chain antibod?))
SE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=>

=> s L8 and (scfv or sc-fv or (single chain antibod?))
        4182 SCFV
         575 SCFVS
        4245 SCFV
             (SCFV OR SCFVS)
       50582 SC
        3177 SCS
       53354 SC
             (SC OR SCS)
        7672 FV
         221 FVS
        7765 FV
             (FV OR FVS)
           8 SC-FV
```

(SC(W)FV)
1418057 SINGLE
3401 SINGLES
1420946 SINGLE
(SINGLE OR SINGLES)
765096 CHAIN
332456 CHAINS
960894 CHAIN
(CHAIN OR CHAINS)
522810 ANTIBOD?
2550 SINGLE CHAIN ANTIBOD?
(SINGLE(W)CHAIN(W)ANTIBOD?)
L9 0 L8 AND (SCFV OR SC-FV OR (SINGLE CHAIN ANTIBOD?))

=> s (membrane transport peptide)
792691 MEMBRANE
340529 MEMBRANES
885590 MEMBRANE
(MEMBRANE OR MEMBRANES)
784339 TRANSPORT
6737 TRANSPORTS
787076 TRANSPORT
(TRANSPORT OR TRANSPORTS)
394289 PEPTIDE
287255 PEPTIDES
503184 PEPTIDE
(PEPTIDE OR PEPTIDES)
L10 17 (MEMBRANE TRANSPORT PEPTIDE)
(MEMBRANE(W)TRANSPORT(W)PEPTIDE)

=> s L10 and (scfv or scfv or single chain antibod?)
4182 SCFV
575 SCFVS
4245 SCFV
(SCFV OR SCFVS)
4182 SCFV
575 SCFVS
4245 SCFV
(SCFV OR SCFVS)
1418057 SINGLE
3401 SINGLES
1420946 SINGLE
(SINGLE OR SINGLES)
765096 CHAIN
332456 CHAINS
960894 CHAIN

(CHAIN OR CHAINS)
522810 ANTIBOD?
2550 SINGLE CHAIN ANTIBOD?
(SINGLE(W)CHAIN(W)ANTIBOD?)
L11 0 L10 AND (SCFV OR SCFV OR SINGLE CHAIN ANTIBOD?)